L. Sengeløv

823 total citations
23 papers, 379 citations indexed

About

L. Sengeløv is a scholar working on Surgery, Oncology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, L. Sengeløv has authored 23 papers receiving a total of 379 indexed citations (citations by other indexed papers that have themselves been cited), including 17 papers in Surgery, 7 papers in Oncology and 6 papers in Pulmonary and Respiratory Medicine. Recurrent topics in L. Sengeløv's work include Bladder and Urothelial Cancer Treatments (13 papers), Urinary and Genital Oncology Studies (5 papers) and Multiple and Secondary Primary Cancers (4 papers). L. Sengeløv is often cited by papers focused on Bladder and Urothelial Cancer Treatments (13 papers), Urinary and Genital Oncology Studies (5 papers) and Multiple and Secondary Primary Cancers (4 papers). L. Sengeløv collaborates with scholars based in Denmark, France and Spain. L. Sengeløv's co-authors include Claus Kamby, Hans von der Maase, Birthe Lund, Svend A. Engelholm, Luigi Dogliotti, Anna Zimmermann, T. Oliver, M. Arning, Malcom J. Moore and Serafino Ricci and has published in prestigious journals such as Journal of Clinical Oncology, The Journal of Urology and Annals of Oncology.

In The Last Decade

L. Sengeløv

23 papers receiving 372 citations

Peers

L. Sengeløv
H. Al‐Abadi Germany
Etsuji Nakano Japan
Carolyn Sasse United States
Gemma Carrera Spain
Roosevelt Anderson United States
Justine Varinot France
Mariel Elena Boyd United States
Oleg Karyakin Sweden
Theodore Stewart Gourdin United States
Naotaka Nishiyama Japan
H. Al‐Abadi Germany
L. Sengeløv
Citations per year, relative to L. Sengeløv L. Sengeløv (= 1×) peers H. Al‐Abadi

Countries citing papers authored by L. Sengeløv

Since Specialization
Citations

This map shows the geographic impact of L. Sengeløv's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by L. Sengeløv with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites L. Sengeløv more than expected).

Fields of papers citing papers by L. Sengeløv

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by L. Sengeløv. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by L. Sengeløv. The network helps show where L. Sengeløv may publish in the future.

Co-authorship network of co-authors of L. Sengeløv

This figure shows the co-authorship network connecting the top 25 collaborators of L. Sengeløv. A scholar is included among the top collaborators of L. Sengeløv based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with L. Sengeløv. L. Sengeløv is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Lund, Cecilia Margareta, Marta Kramer Mikkelsen, Susann Theile, et al.. (2022). Age-related Differences in Recall of Information and Handling of Chemotherapy-related Side Effects in Cancer Patients: The ReCap Study. The Oncologist. 27(2). e185–e193. 6 indexed citations
2.
3.
Kongsted, Per, Eva Ellebæk, Troels Holz Borch, et al.. (2016). Dendritic cell vaccination in combination with docetaxel for patients with prostate cancer – a randomized phase II study. Annals of Oncology. 27. vi371–vi371. 3 indexed citations
4.
Heidenreich, Axel, Sergio Bracarda, M.D. Mason, et al.. (2013). 106 Cabazitaxel adverse events are manageable in senior adults with metastatic castration-resistant prostate cancer (mCRPC): Results of the European Compassionate Use Programme. European Urology Supplements. 12(1). e106–e107. 1 indexed citations
5.
Heidenreich, Axel, Sergio Bracarda, Malcolm D. Mason, et al.. (2012). Tolerability of Cabazitaxel in Senior Adults with Metastatic Castration-Resistant Prostate Cancer (MCRPC) in Europe. Annals of Oncology. 23. ix307–ix307. 4 indexed citations
6.
Ou, Yang, M. Dror Michaelson, L. Sengeløv, et al.. (2011). Randomized, placebo-controlled, phase III trial of sunitinib in combination with prednisone (SU+P) versus prednisone (P) alone in men with progressive metastatic castration-resistant prostate cancer (mCRPC).. Journal of Clinical Oncology. 29(15_suppl). 4515–4515. 49 indexed citations
7.
Maase, Hans von der, Christine Théodore, L. Sengeløv, et al.. (2008). Randomised phase III trial of vinflunine (V) plus best supportive care (B) vs B alone as 2nd line therapy after a platinum-containing regimen in advanced transitional cell carcinoma of the urothelium (TCCU). Journal of Clinical Oncology. 26(15_suppl). 5028–5028. 15 indexed citations
8.
Barriuso, Jorge, Gedske Daugaard, Sophia Frentzas, et al.. (2008). 213 POSTER Phase II multicenter trial of belinostat (PXD101) in combination with carboplatin and paclitaxel (BelCaP) for patients (pts) with transitional cell carcinoma (TCC) of the bladder. European Journal of Cancer Supplements. 6(12). 67–68. 3 indexed citations
9.
Maase, Hans von der, L. Sengeløv, John Roberts, et al.. (2006). UROLOGICAL ONCOLOGY: BLADDER, PENIS AND URETHRA CANCER, AND BASIC PRINCIPLES OF ONCOLOGY Long-Term Survival Results of a Randomized Trial Comparing Gemcitabine Plus Cisplatin, With Methotrexate, Vinblastine, Doxorubicin, Plus Cisplatin in Patients With Bladder Cancer. 1 indexed citations
10.
Maase, Hans von der, L. Sengeløv, J.T. Roberts, et al.. (2006). Long-Term Survival Results of a Randomized Trial Comparing Gemcitabine Plus Cisplatin, with Methotrexate, Vinblastine, Doxorubicin, Plus Cisplatin in Patients with Bladder Cancer. The Journal of Urology. 175(2). 482–482. 112 indexed citations
11.
Sengeløv, L., et al.. (2005). [Chemotherapy as a supplement to radical treatment of patients with locally advanced bladder cancer].. PubMed. 167(7). 749–51. 1 indexed citations
12.
Sengeløv, L.. (2003). ESMO Minimum Clinical Recommendations for diagnosis, treatment and follow-up of invasive bladder cancer. Annals of Oncology. 14(7). 1008–1009. 2 indexed citations
13.
Kamby, Claus & L. Sengeløv. (1999). Survival and Pattern of Failure Following Locoregional Recurrence of Breast Cancer. Clinical Oncology. 11(3). 156–163. 22 indexed citations
14.
Sengeløv, L., Claus Kamby, Birthe Lund, & Svend A. Engelholm. (1998). Docetaxel and cisplatin in metastatic urothelial cancer: a phase II study.. Journal of Clinical Oncology. 16(10). 3392–3397. 62 indexed citations
15.
Sengeløv, L.. (1998). [Repeated irradiation of cancer patients].. PubMed. 160(32). 4610–3. 1 indexed citations
16.
Sengeløv, L., Thomas Horn, & K. Steven. (1997). p53 nuclear immunoreactivity as a predictor of response and outcome following chemotherapy for metastatic bladder cancer. Journal of Cancer Research and Clinical Oncology. 123(10). 565–570. 30 indexed citations
17.
Sengeløv, L., et al.. (1997). Treatment outcome following radiotherapy in elderly patients with bladder cancer. Radiotherapy and Oncology. 44(1). 53–58. 19 indexed citations
18.
Sengeløv, L., Claus Kamby, & Hans von der Maase. (1995). 1163 Pattern of metastases in relation to characteristics of primary tumor and treatment in patients (pts) with disseminated urothelial carcinoma (UC). European Journal of Cancer. 31. S243–S243. 2 indexed citations
19.
Lorentzen, Torben, et al.. (1995). Ultrasonically Guided Insertion of a Peritoneo-Gastric Shunt in Patients with Malignant Ascites. Acta Radiologica. 36(4-6). 481–484. 16 indexed citations
20.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by H. Al‐Abadi Breakdown of academic impact, for papers by Etsuji Nakano Breakdown of academic impact, for papers by Carolyn Sasse Breakdown of academic impact, for papers by Gemma Carrera Breakdown of academic impact, for papers by Roosevelt Anderson Breakdown of academic impact, for papers by Justine Varinot Breakdown of academic impact, for papers by Mariel Elena Boyd Breakdown of academic impact, for papers by Oleg Karyakin Breakdown of academic impact, for papers by Theodore Stewart Gourdin Breakdown of academic impact, for papers by Naotaka Nishiyama
Rankless by CCL
2026